Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $9.30 USD
Change Today +0.08 / 0.87%
Volume 1.1M
ARAY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

accuray inc (ARAY) Snapshot

Open
$9.21
Previous Close
$9.22
Day High
$9.47
Day Low
$9.12
52 Week High
04/1/14 - $9.80
52 Week Low
10/30/14 - $5.99
Market Cap
730.0M
Average Volume 10 Days
1.1M
EPS TTM
$-0.60
Shares Outstanding
78.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACCURAY INC (ARAY)

accuray inc (ARAY) Related Businessweek News

No Related Businessweek News Found

accuray inc (ARAY) Details

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. Accuray Incorporated markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors in Europe, Japan and rest of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.

1,026 Employees
Last Reported Date: 08/29/14
Founded in 1990

accuray inc (ARAY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $637.5K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $293.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $368.1K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $330.6K
Compensation as of Fiscal Year 2014.

accuray inc (ARAY) Key Developments

Accuray Incorporated Approves the Amendment and Restatement of the Amended and Restated Bylaws

Accuray Incorporated announced that on March 19, 2015, the company's Board of Directors approved the amendment and restatement of the company's amended and restated Bylaws. The Bylaws were amended and restated to provide the following, among other things: (a) With respect to proposals and director nominations brought before a meeting by stockholders. (b) The Amended Bylaws clarify when an election is deemed to be contested. (c) The Amended Bylaws provide a more detailed framework for the chairperson and secretary of any stockholder meeting, except to the extent inconsistent with rules adopted by the Board, to regulate the conduct of stockholder meetings. (d) The company's Certificate of Incorporation provided that directors may be removed (i) for cause by affirmative vote of a majority of the outstanding stock entitled to vote at an election of directors, and (ii) without cause by an affirmative vote of 66 2/3% of the outstanding stock entitled to vote at an election of directors. Notwithstanding that provision, the company's Bylaws had provided that the directors may only be removed for cause, purporting to be more restrictive. The Amended Bylaws conforms the Bylaws to the company's Certificate of Incorporation to provide that, any director may be removed (i) for cause by affirmative vote of a majority of the outstanding stock entitled to vote at an election of directors, and (ii) without cause by an affirmative vote of 66 2/3% of the outstanding stock entitled to vote at an election of directors. (e) The Amended Bylaws provide that in certain cases where a communication is required, notice by electronic means shall be sufficient to fulfill the requirement. (f) The Amended Bylaws set out procedural matters relating to contracts or transactions involving interested directors consistent with applicable law. (g) Finally, the Amended Bylaws include a new Article X.

Accuray and Christie InnoMed Sign Exclusive Sales Agent Agreements for Radiation Therapy Systems in Canada

Accuray Incorporated and Christie InnoMed Inc. announced that they have entered into sales agent agreements involving the CyberKnife® and TomoTherapy® System product portfolios in Canada. Under the terms of these agreements, Christie InnoMed will be the exclusive sales agent for Accuray products in this region.

Accuray Incorporated Completes First Patient Treatment Using the CyberKnife® M6™ System with the InCise™ Multileaf Collimator

Accuray Incorporated announced that the first patient treatment has been completed using the CyberKnife® M6™ System with the InCise™ Multileaf Collimator (MLC). The treatment was administered as a multidisciplinary effort between Dr. Steven Burton from the Department of Radiation Oncology and Dr. Johnathan Engh from the Department of Neurosurgery at UPMC in Pittsburgh, Pennsylvania. UPMC was one of the InCise MLC evaluation sites working in collaboration with Accuray. The M6 Series delivers radiosurgery and stereotactic body radiation therapy, enabling precise, high-quality dose distributions to be confidently administered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The system is able to adjust and automatically stay on target in real-time, accounting for patient and tumor motion. CyberKnife is the only robotic radiosurgery system available which delivers such high precision treatments for intra- and extra-cranial disease sites throughout the body.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARAY:US $9.30 USD +0.08

ARAY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Elekta AB kr77.50 SEK +0.05
Koninklijke Philips NV €26.27 EUR +0.23
Mitsubishi Heavy Industries Ltd ¥662.30 JPY -8.50
RaySearch Laboratories AB kr69.75 SEK +3.00
Varian Medical Systems Inc $93.74 USD +0.87
View Industry Companies
 

Industry Analysis

ARAY

Industry Average

Valuation ARAY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.9x
Price/Book 9.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACCURAY INC, please visit www.accuray.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.